Quarterly ResultMay 6, 2026, 09:46 AM
Evotec Q1 Revenue Down 22% to €156.6M; Horizon Transformation Underway
AI Summary
Evotec SE reported a challenging first quarter for 2026, with group revenues declining 22% to €156.6 million and adjusted Group EBITDA turning negative at €(21.9) million, primarily due to a strong prior-year comparison and market softness. Despite the financial downturn, the company confirmed its full-year 2026 guidance and is actively implementing its 'Horizon' strategic transformation, incurring €75.0 million in reorganization costs. Evotec also announced key leadership appointments, expects significant proceeds from an investment exit, and initiated a strategic review of its portfolio and capital structure.
Key Highlights
- Group revenues decreased 22% to €156.6 million in Q1 2026 (3M 2025: €200.0 million).
- Adjusted Group EBITDA was €(21.9) million, down from €3.1 million in Q1 2025.
- Net loss for the quarter widened to €(121.9) million (3M 2025: €(31.6) million).
- Reorganization costs of €75.0 million were incurred for the 'Horizon' transformation program.
- Evotec expects to receive approximately $100 million from its equity stake in Tubulis acquisition by Gilead Sciences.
- Full-year 2026 revenue guidance confirmed at €700-780 million (€730-810 million CER).
- Claire Hinshelwood appointed CFO and Dr. Ingrid Müller COO, effective May 1, 2026.
- The company initiated a comprehensive evaluation of strategic options at the Group level.